Some information in this summary may be different from the approved labelling for
carfilzomib. Your healthcare professional should refer to the full prescribing
information for proper use of carfilzomib.
2. Who Sponsored This Study?
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA
Phone (United States): +1 805-447-1000
Amgen Inc. is the sponsor of the study and also the manufacturer of carfilzomib, the
medicine tested in the study. Amgen would like to thank everyone who participated
in this study and feels it is important to share the results of this study.
3. General Information About the Clinical Trial
Where and when was the study done?
 This study took place in Australia, Belgium, Canada, Czech Republic, Denmark,
Finland, France, Germany, Greece, Hungary, Italy, Japan, New Zealand,
Norway, Poland, Romania, Spain, Sweden, United States, and United Kingdom
 The study began in September 2015 and ended in January 2019
 The study was completed as planned.
Why was the study done?
Multiple myeloma is cancer that begins in the plasma cells, which are a type of white
blood cell. Patients can be treated for multiple myeloma. However, multiple
myeloma could come back after treatment.
2